Experienced in Peripheral Neuropathy

Olivier Bouche

Reims, FR 
Experienced in Peripheral Neuropathy
Reims, FR 
OverviewLocationsClinical Research

Overview

Olivier Bouche practices in Reims, France. Mr. Bouche is rated as an Experienced expert by MediFind in the treatment of Peripheral Neuropathy. His top areas of expertise are Colorectal Cancer, Gastrointestinal Stromal Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 304 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 1 clinical trial in the study of Peripheral Neuropathy.

Gender
Male

Locations

Reims, 51100, France
Other Locations
Tours, France
La Timone, AMU
Marseille, France
Paris, France
Champagne-sur-seine, France
Dijon, 21000, France
CHU Poitiers
Poitiers, France
Besancon, France
Lille, France
CH Blois
Blois, France
Amiens, France
CHU St Etienne, Saint-etienne, France
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study
Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drug: Trifluridine/Tipiracil
Study Phase: Phase 2
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 Study)
A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: FOLFIRI, OSE2101, Nivolumab
Study Phase: Phase 2
MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients
MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Olaparib, Durvalumab, Selumetinib, FOLFIRI
Study Phase: Phase 2
A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1
A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug
Study Phase: Phase 3
Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE).
Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE).
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: June 12, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 3
A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer
A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Regorafenib, Trifluridine/Tipiracil
Study Phase: Phase 2
Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma (ALIX)
Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma (ALIX)
Enrollment Status: Terminated
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: XELOXIRI-3, Gemcitabine
Study Phase: Phase 2
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: FOLFIRINOX, LV5FU2, FOLFIRI.3, Gemcitabine
Study Phase: Phase 2
A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Other, Drug
Study Drug: Lenvatinib
Study Phase: Phase 2
Evaluation of the Efficacy of Donepezil in the Treatment of Oxaliplatin-induced Peripheral Neuropathy: Proof of Concept Study
Evaluation of the Efficacy of Donepezil in the Treatment of Oxaliplatin-induced Peripheral Neuropathy: Proof of Concept Study
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drug: DONEPEZIL
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
Enrollment Status: Completed
Publish Date: January 09, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Folinic Acid, 5-Fluoro-uracil, Oxaliplatin, Irinotecan, L-folinic
Study Phase: Phase 3
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug
Study Drug: Imatinib Maintenance
Study Phase: Phase 3
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients : AVapritinib Real-life observatTORy
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients : AVapritinib Real-life observatTORy
Enrollment Status: Active_not_recruiting
Publish Date: December 26, 2023
Intervention Type: Drug
A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine
A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Drugs: Trifluridine/Tipiracil, Oxaliplatin
Study Phase: Phase 2
Study of the Practice of Debiri in France: Indications, Associations to Systemic Treatments, Efficiency, Tolerance - Prospective Practice Survey
Study of the Practice of Debiri in France: Indications, Associations to Systemic Treatments, Efficiency, Tolerance - Prospective Practice Survey
Enrollment Status: Unknown
Publish Date: August 19, 2022
Intervention Type: Drug
CIRCE: Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
CIRCE: Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
Enrollment Status: Completed
Publish Date: April 21, 2022
Intervention Type: Procedure, Biological
Study Phase: Not Applicable
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Enrollment Status: Completed
Publish Date: April 04, 2022
Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer
Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: March 24, 2022
Intervention Type: Drug
Study Drugs: Cetuximab, FOLFIRI
Study Phase: Phase 2
A Prospective Study Assessing Whether Immunoscore Colon Test Impacts the Choice of Adjuvant Chemotherapy, in a Multidisciplinary Meeting, for Treating Non-metastatic Colon Cancer Patients After Curative-intent Surgery
A Prospective Study Assessing Whether Immunoscore Colon Test Impacts the Choice of Adjuvant Chemotherapy, in a Multidisciplinary Meeting, for Treating Non-metastatic Colon Cancer Patients After Curative-intent Surgery
Enrollment Status: Withdrawn
Publish Date: August 30, 2019
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective
A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective
Enrollment Status: Completed
Publish Date: August 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 22 Less Clinical Trials

304 Total Publications

Overcoming language barriers to enhance pharmaceutical care: Design and validation of a pictogram-based tool for cancer patients.
Overcoming language barriers to enhance pharmaceutical care: Design and validation of a pictogram-based tool for cancer patients.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: August 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bouche's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile